-
摘要: 多发内分泌肿瘤(multiple endocrine neoplasia, MEN)是一种累及多种内分泌腺体的常染色体显性遗传病, 常同时或先后发生两种以上内分泌肿瘤。MEN相关肿瘤包括原发性甲状旁腺功能亢进症、嗜铬细胞瘤、甲状腺髓样癌、胰腺神经内分泌肿瘤和垂体瘤等, 这些肿瘤的临床特点和治疗方案与散发性肿瘤比较既有相似之处, 亦有其特殊性。近年来, MEN相关肿瘤的治疗已经达成了一些共识, 但仍存在较多争议, 手术时机及手术切除范围是争议的焦点。Abstract: Multiple endocrine neoplasia (MEN) is an autosomal dominant hereditary disease involving multiple endocrine glands with two or more endocrine tumors occurring simultaneously or successively. MEN-related tumors include primary hyperparathyroidism, pheochromocytoma, medullary thyroid cancer, pancreatic neuroendocrine neoplasia, and pituitary adenoma, etc. Although the clinical characteristics and treatment of these tumors are similar to those of sporadic tumors, there are differences in some aspects. In recent years, there has been some consensus achieved on the treatment of MEN-related tumors. But there are also some controversies. The timing and scope of surgical resection are the focus of controversies.
-
Key words:
- multiple endocrine neoplasia /
- treatment /
- surgical timing
利益冲突 无 -
[1] Al-Salameh A, Baudry C, Cohen R. Update on multiple endocrine neoplasia Type 1 and 2[J]. Presse Med, 2018, 47:722-731. doi: 10.1016/j.lpm.2018.03.005 [2] Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1(MEN1)[J]. J Clin Endocrinol Metab, 2012, 97:2990-3011. doi: 10.1210/jc.2012-1230 [3] Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome[J]. N Engl J Med, 1999, 341:635-644. doi: 10.1056/NEJM199908263410902 [4] 中华医学会骨质疏松和骨矿盐疾病分会, 中华医学会内分泌分会代谢性骨病学组.原发性甲状旁腺功能亢进症诊疗指南[J].中华骨质疏松和骨矿盐疾病杂志, 2014, 7:187-198. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhgzsshgkyjbzz201403003 [5] Lairmore TC, Govednik CM, Quinn CE, et al. A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1[J]. Surgery, 2014, 156:1326-1335. doi: 10.1016/j.surg.2014.08.006 [6] 中华医学会内分泌学分会肾上腺学组.嗜铬细胞瘤和副神经节瘤诊断治疗的专家共识[J].中华内分泌代谢杂志, 2016, 32:181-187. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnfmdx201603002 [7] 邓建华, 李汉忠.嗜铬细胞瘤/副神经节瘤基因突变相关遗传综合征[J].协和医学杂志, 2015:161-165. http://www.cqvip.com/QK/70803X/201503/665023395.html [8] Castinetti F, Qi XP, Walz MK, et al. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2:an international retrospective population-based study[J]. Lancet Oncol, 2014, 15:648-655. doi: 10.1016/S1470-2045(14)70154-8 [9] 樊华, 张玉石, 李汉忠, 等.保留肾上腺功能的腹腔镜双侧嗜铬细胞瘤切除术[J].中华内分泌外科杂志, 2017, 11:184-187. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=nfmwk201703003 [10] Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25:567-610. doi: 10.1089/thy.2014.0335 [11] Raue F, Frank-Raue K. Update on Multiple Endocrine Neoplasia Type 2:Focus on Medullary Thyroid Carcinoma[J]. J Endocr Soc, 2018, 2:933-943. doi: 10.1210/js.2018-00178 [12] Krampitz GW, Norton JA. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma[J]. Cancer, 2014, 120:1920-1931. doi: 10.1002/cncr.28661 [13] Marx SJ. Recent Topics Around Multiple Endocrine Neop-lasia Type 1[J]. J Clin Endocrinol Metab, 2018, 103:1296-1301. doi: 10.1210/jc.2017-02340 [14] Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Funct-ional Pancreatic Neuroendocrine Tumors[J]. Neuroendocrinology, 2016, 103:153-171. doi: 10.1159/000443171 [15] Shah M, Goldner W, Benson A, et al. NCCN Clinical Practice Guidelines in Oncology:Neuroendocrine and Adrenal Tumors[J]. J Natl Compr Canc Netw, 2018, 16:693-702. doi: 10.6004/jnccn.2018.0056 [16] Albers MB, Manoharan J, Bartsch DK. Contemporary surg-ical management of the Zollinger-Ellison syndrome in mul-tiple endocrine neoplasia type 1[J]. Best Pract Res Clin Endocrinol Metab, 2019, 33:101318. doi: 10.1016/j.beem.2019.101318 [17] Pavel M, Valle JW, Eriksson B, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms:Systemic Therapy-Biotherapy and Novel Targeted Agents[J]. Neuroendocrinology, 2017, 105:266-280. doi: 10.1159/000471880 [18] Hicks R, Kwekkeboom D, Krenning E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroen-docrine Neoplasia Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues[J]. Neuroendocrinology, 2017, 105:295-309. doi: 10.1159/000475526 [19] Wu Y, Gao L, Guo X, et al. Pituitary adenomas in patients with multiple endocrine neoplasia type 1:a single-center experience in China[J]. Pituitary, 2019, 22:113-123. doi: 10.1007/s11102-019-00939-x [20] De Laat JM, Dekkers OM, Pieterman CR, et al. Long-Term Natural Course of Pituitary Tumors in Patients With MEN1:Results From the DutchMEN1 Study Group (DMSG)[J]. J Clin Endocrinol Metab, 2015, 100:3288-3296. doi: 10.1210/JC.2015-2015
点击查看大图
计量
- 文章访问数: 346
- HTML全文浏览量: 40
- PDF下载量: 128
- 被引次数: 0